Full Length Research Paper
References
|
Afsar CU, Gunaldı M, Okuturlar Y, Gedikbası A, Tiken EE, Kahraman S, Karabulut M (2015). Paraoxonase-1 and arylesterase activities in patients with colorectal cancer. International Journal of Clinical and Experimental Medicine 8(11):21599-21604. |
|
|
Aiello M, Vella N, Cannav O, Scalisi A, Spandidos D, Toffoli G, Buonadonna A, libra M, Stivala F (2011). Role of genetic polymorphisms and mutations in colorectal cancer therapy. Molecular Medicine Reports 4:203-208. |
|
|
Alani H, Tamimi A, Tamimi N (2014). Cardiovascular co-morbidity in chronic kidney disease: current knowledge and future research needs. World Journal of Nephrology 3(4):156-168. |
|
|
Annemieke R, Albert G, Huib C, Stephan K, Andre K (2003). Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. Journal (370):737-749. |
|
|
Blandin C, Gausson V, Latscha B (2004). Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochim Biophys Acta 1689:91-102. |
|
|
Ceccacci E, Minucci S (2016). Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia. British Journal of Cancer 114(6):605-611. |
|
|
Ceron J, Tecles F, Tvarijonaviciute A (2014). Serum paraoxonase 1 (PON1) measurement: an update. BMC Veterinary Research 10:74. |
|
|
Choudhary C, Kumar C, Gnad F, Nielsen M, Rehman M, Walther T (2009). Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325(5942):834-840. |
|
|
Eckerson HW, Wyte CM, Du BN (1983). The human serum paraoxonase/arylesterase polymorphism. Identification of phenotypes by their response to salts. American Journal of Human Genetics 35(2):214-227. |
|
|
Eldeeb H, Ahmed N, Abdelfattah S, Abdelzaher MH, Mohammad M, Abolfotoh M, Hassan Y, Hassan M (2017). Paraoxonase activity and gene polymorphism in colorectal cancer Egyptian patients. New York Science Journal 10(4):27-36. |
|
|
Elkiran ET, Mar N, Aygen B, Gursu F, Karaoglu A, Koca S (2007). Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 7(48):1471-2407. |
|
|
Ellidag HY, Eren E, Aydin O, Neselioglu S, Yilmaz N (2014). The phenotype distribution of paraoxonase-1 in patients with multiple myeloma, bladder, and colorectal cancer. Journal of Medical Biochemistry 33(3):252-258. |
|
|
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in Globocan 2012. International Journal of Cancer 136(5):359-386. |
|
|
Figueroa-González G, Pérez-Plasencia C (2017). Strategies for the evaluation of DNA damage and repair mechanisms in cancer. Oncology Letters 13(6):3982-3988. |
|
|
Garin MC, Abbott C, Messmer S, Mackness M, Durrington P, Pometta D, James RW (1994). Quantification of human serum paraoxonase by enzyme linked immunoassay: population differences in protein concentrations. Biochemistry Journal 30:549-554. |
|
|
Gonzalez E, Bajo M, Carrero J, Lindholm B, Grande C, Villanueva R, Peso G, Almirón M, Iglesias P, Díez J, Selgas R (2015). An increase of plasma advanced oxidation protein products levels is associated with cardiovascular risk in incident peritoneal dialysis patients: a pilot study. Oxidative Medicine and Cellular Longevity 2015(219569):1-6. |
|
|
Guo C, Li X, Wang R, Yu J, Ye M, Mao L, Zhang S and Zheng S (2016). Association between oxidative DNA damage and risk of colorectal cancer: Sensitive determination of urinary 8-Hydroxy-2′-deoxyguanosine by UPLC-MS/MS. Analysis Scientific Reports. 32581:1038-32581. |
|
|
Gupta N, Binukumar BK, Singh S, Sunkaria A, Kandimalla R, Bhansali A, Gill KD (2011). Serum paraoxonase-1 (PON1) activities (PONase/AREase) and polymorphisms in patients with type 2 diabetes mellitus in a North-West Indian population. Gene 487(1):88-95. |
|
|
Hopps E, Caimi G (2013). Protein oxidation in metabolic syndrome. Clinical and Investigative Medicine 36(1):1-8. |
|
|
Hussein Y, Gharib A, Etewa R, ElSawy W (2011). Association of L55M and Q192R polymorphisms in paraoxonase 1 (PON1) gene with breast cancer risk and their clinical significance. Molecular and Cellular Biochemistry 351:117-123. |
|
|
Jin K, Park J, Choi W, Lee J, Kim J, Nam J (2008). Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. Journal of Gynecologic Oncology 19(3):185-190. |
|
|
Johnson N, Lachance J (2012). The genetics of sex chromosomes: evolution and implications for hybrid incompatibility. Annals of the New York Academy of Sciences 1256:1-22. |
|
|
Júnior A, Paz M, Silva L, Carvalho S, Sobral A, Machado K, Ferreira P, Satyal P, Freitas R, Cavalcante A (2015). Serum oxidative stress markers and genotoxic profile induced by chemotherapy in patients with breast cancer. A pilot study. Oxidative Medicine and Cellular Longevity 212964: 1-11. |
|
|
Kilic SS, Aydin S, Kilic N, Erman F, Aydin S, Celik I (2005). Serum arylesterase and paraoxonase activity in patients with chronic hepatitis. World Journal of Gastroenterology 11(46):7351-7354. |
|
|
Li L, Dai H, Ye M, Wang S, Xiao X, Zheng J, Chen H, Luo Y and Liu J (2012). Lycorine induces cell-cycle arrest in the G0/G1 phase in K562 cells via HDAC inhibition. Cancer Cell International 12(1): 49-54. |
|
|
Li Z, Pearlman AH, Hsieh P (2015). DNA mismatch repair and the DNA damage response. DNA Repair (Amst). 38:94-101. |
|
|
Ma N, Luo Y, Wang Y, Liao C, Ye WC, Jiang S (2016). Selective histone deacetylase inhibitors with anticancer activity. Current Topics in Medicinal Chemistry 16:415-426. |
|
|
Marques S, Fernandes R, Nóbrega S, Medeiros A, Gonçalves O, Batista S (2014). Influence of patient age and colorectal polyp size on histopathology findings. Arquivos Brasileiros de Cirurgia Digestiva. 27(2): 109-113. |
|
|
Marzouk O, Schofield J (2011). Review of histopathological and molecular prognostic features in colorectal cancer. Cancers 3:2767-2810. |
|
|
Morry J, Ngamcherdtrakul W, Yantasee W (2017). Oxidative stress in cancer and fibrosis: Opportunity for therapeutic intervention with antioxidant compounds, enzymes, and nanoparticles. Redox Biology 11: 240-253. |
|
|
Mukthapura A, Shimogga A, Sudha KV, Shetty B, Rao G (2013). Oxidative products of proteins and antioxidants potential of thiols in gastric carcinoma patients. Journal of Medical Biochemistry 29:102-106. |
|
|
Nayyar A, Khan M, Kr V, Suman B, Gayitri HC, Anitha M (2012). Malaysian Serum total protein, albumin and advanced oxidation protein products (AOPP) implications in oral squamous cell carcinoma Malaysian Journal of Pathology 34(1):47-52. |
|
|
Ouyang W, Zhang D, Li J, Verma U, Costa M, Huang C (2009). Soluble and insoluble nickel compounds exert a differential inhibitory effect on cell growth through IKKα-dependent cyclin D1 down regulation. Journal of Cellular Physiology 218(1):205-214. |
|
|
Prasad S, Khadatare P, Roy I (2011). Effect of chemical chaperones in improving the solubility of recombinant proteins in escherichia coli. Aplied and Environmental Microbiology 77(13):4603-4609. |
|
|
Salud N, Álvarez P, Garrido J, Carrasco E, Aránega A, Serrano F (2016). Antioxidant intake and antitumor therapy: toward nutritional recommendations for optimal results. Oxidative Medicine and Cellular Longevity 6719534. |
|
|
Schaffer HE, Sederoff RR (1981). Improved estimation of DNA fragment lengths from agarose gels. Analytical Biochemistry115: 113-122. |
|
|
Shikhar S, Theresa K, Peter A (2010). Epigenetics in cancer. Carcinogenesis 31(1):27-36. |
|
|
Singh B, Zhou H, Li J, Tipton T, Wang B, Shao G, Gilbert E, Li Q, Jiang S (2012). Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers. Future Oncology 7(12):1415-1428. |
|
|
Tandon N, Ramakrishnan V, Kumar S (2016). Clinical use and applications of histone deacetylase inhibitors in multiple myeloma. Clinical Pharmacology 8:35-44. |
|
|
Wang Z, Li S, Cao Y, Tian X, Zeng R, Liao DF, Cao D (2016). Oxidative stress and carbonyl lesions in ulcerative colitis and associated colorectal cancer. Oxidative Medicine and Cellular Longevity 9875298. |
|
|
Xu H, Rodriguez I, Qureshi A (2014). Increased levels of modified advanced oxidation protein products are associated with central and peripheral blood pressure in peritoneal dialysis patients. Peritoneal Dialysis International 1:1-11. |
|
|
Zhou Q, Wu S, Jiang J (2012). Accumulation of circulating dvanced oxidation protein products is an independent risk factor for ischemic heart disease in maintenance haemodialysis patients. Nephrology 17(7):642-649. |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
